- Home
- SPHL vs APLM Comparison
SPHL vs APLM Comparison
Compare SPHL & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHL
- APLM
- Stock Information
- Founded
- SPHL 2002
- APLM 2016
- Country
- SPHL Singapore
- APLM United States
- Employees
- SPHL N/A
- APLM N/A
- Industry
- SPHL Homebuilding
- APLM Blank Checks
- Sector
- SPHL Consumer Discretionary
- APLM Finance
- Exchange
- SPHL Nasdaq
- APLM Nasdaq
- Market Cap
- SPHL 5.7M
- APLM 6.9M
- IPO Year
- SPHL 2024
- APLM N/A
- Fundamental
- Price
- SPHL $0.60
- APLM $4.89
- Analyst Decision
- SPHL
- APLM
- Analyst Count
- SPHL 0
- APLM 0
- Target Price
- SPHL N/A
- APLM N/A
- AVG Volume (30 Days)
- SPHL 1.5M
- APLM 6.9K
- Earning Date
- SPHL 02-21-2025
- APLM 04-03-2025
- Dividend Yield
- SPHL N/A
- APLM N/A
- EPS Growth
- SPHL N/A
- APLM N/A
- EPS
- SPHL N/A
- APLM N/A
- Revenue
- SPHL $6,456,601.00
- APLM $198,000.00
- Revenue This Year
- SPHL N/A
- APLM $415.15
- Revenue Next Year
- SPHL N/A
- APLM N/A
- P/E Ratio
- SPHL N/A
- APLM N/A
- Revenue Growth
- SPHL N/A
- APLM N/A
- 52 Week Low
- SPHL $0.35
- APLM $4.71
- 52 Week High
- SPHL $7.80
- APLM $42.00
- Technical
- Relative Strength Index (RSI)
- SPHL N/A
- APLM 35.08
- Support Level
- SPHL N/A
- APLM $4.63
- Resistance Level
- SPHL N/A
- APLM $5.45
- Average True Range (ATR)
- SPHL 0.00
- APLM 0.54
- MACD
- SPHL 0.00
- APLM -0.10
- Stochastic Oscillator
- SPHL 0.00
- APLM 16.03
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.